Buy & Sell Veritone Inc (VERI) – Veritone Inc Price Today
Key Stats
- $132.92MMarket Cap
- TechnologySector
- -48.75%3M Drawdown
- $164.95MEnterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 10 daysTypical Hold Time
Veritone Inc (VERI) is currently valued at a market capitalization of $132.92M, with an enterprise value of $164.95M. Over the past 52 weeks, Veritone Inc has traded between a low of $1.22 and a high of $8.39, highlighting its annual price range. Over the past three months, Veritone Inc has recorded a drawdown of -48.75%, reflecting recent price volatility. On average, investors hold Veritone Inc for approximately 10 days, indicating typical investor behavior on the platform.
About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Most Recent News
FTI Consulting hires Jerome Nyssen to boost AI-driven risk and compliance advisory in Australia.
FTI Consulting appointed Jerome Nyssen as Senior Managing Director in its Risk Advisory practice in Australia to enhance AI-driven risk, compliance, and governance services. Nyssen brings 25 years of experience across financial services and technolog...

AI/R advances AI integration in business with Databricks, achieving Gold partner status and boosting client results.
AI/R, a technology company specializing in Agentic AI, has deepened its partnership with Databricks, achieving Gold partner status and expanding its certifications from 11 to over 100. This growth enables AI/R to deliver advanced AI and data solution...

Lebrikizumab sustains atopic dermatitis clearance up to 2 years with less frequent dosing, per new long-term data.
New long-term data from the ADjoin trial shows that lebrikizumab, an injectable treatment for moderate to severe atopic dermatitis, maintains skin clearance and reduces itching for up to 2 years even with monthly dosing instead of biweekly. About 76%...
